. More pronounced improvement in the left ventricular diastolic dysfunction (delta E/A 0.34 vs. 0.12, p = 0.017) (Cardiol J 2016; 23, 2: 132-140) 
Introduction
Arterial hypertension (AH) is the main widespread cardiovascular risk factor in the world's population. Unfortunately, the majority of hypertensives still do not achieve satisfactory blood pressure (BP) control [1, 2] . Current guidelines [2, 3] emphasize a need for personalized hypotensive therapy. It may be supported by individualized assessment of hemodynamic alterations associated with increased BP. One of the promising diagnostic techniques is impedance cardiography (ICG), useful in the identification of hyperdynamic heart function, fluid retention, and increased vascular resistance. Hemodynamically-guided pharmacotherapy based on impedance variables, such as cardiac index (CI), thoracic fluid content (TFC) and systemic vascular resistance index (SVRI), was previously evaluated in randomized, prospective and controlled trials and revealed to be more beneficial than the empiric treatment [4] [5] [6] [7] [8] . However, the period of observation in those trials was short (3 months) and BP reduction was the only evaluated hemodynamic effect.
Thus, there is no evidence (1) if this effect persists in longer observation period and (2) whether this therapeutic approach has influence on other features related to cardiovascular hemodynamics, especially these of prognostic value (central BP, myocardial hypertrophy) [2, 9] .
Therefore, the aim of this study was to estimate the influence of ICG-guided antihypertensive therapy on: (1) brachial and (2) central BP, (3) impedance-derived hemodynamic profile and (4) echocardiographic indices of left chambers' morphology and function evaluated after 12 months in a randomized, prospective and controlled trial.
Methods

Study population
The study group consisted of patients with at least 3-month history of AH defined according to the European Society of Cardiology (ESC) guidelines [2] . Exclusion criteria were: (1) confirmed secondary AH, (2) AH treated with three or more medicines before recruitment, (3) significant heart failure (left ventricular ejection fraction < 45%), (4) cardiomyopathy (i.e. hypertrophic cardiomyopathy), (5) significant heart rhythm disorders, (6) significant valvular disease, (7) kidney failure (estimated glomerular filtration rate < 60 mL/ /min/1.73 m 2 ), (8) 
Study design
The study was randomized (1:1), prospective and simultaneously controlled by conventional treatment. Initial clinical evaluation was performed via face to face or telephone conversations. Patients who had taken medicines before the study were advised to discontinue using them (minimum 7 days of pharmacological "wash-out"). Next, all patients underwent complete clinical examination including: interview and physical examination, office blood pressure measurement (OBPM), ambulatory blood pressure monitoring (ABPM), impedance cardiography, applanation tonometry, and echocardiography.
The subjects were allocated to two groups according to the pre-established random order (by using the method of randomly permuted blocks available at www.randomization.com): (1) empiric (GE) and (2) hemodynamic (HD). Treatment choice in both groups was made by independent researchers.
The evaluation of treatment effects was performed after 12 months and blinded to the group allocation. Differences between groups in BP reduction and obtained BP control were considered main final points (per protocol analysis). Figure 1 shows the protocol flowchart for observation time of mean 376 ± 25 days. The subjects were evaluated 3 times (no additional interim visits were performed). Twenty-three patients were excluded from the final analysis (GE: 7 subjects; HD: 16 subjects). Twenty-two of them resigned from control visit and 1 woman stopped the pharmacotherapy due to pregnancy. The final analysis comprised of 121 subjects (Fig. 1) .
Office blood pressure measurement
Office systolic and diastolic blood pressure measurement was performed during morning hours (7.30 a.m.-8.30 a.m.) automatically (Omron M4 Plus, Japan) by a technique compliant with the ESC guidelines [2] .
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Ambulatory blood pressure monitoring
Ambulatory blood pressure monitoring started in the morning hours (Spacelabs 90207, Spacelabs, Medical Inc., Redmond, USA). Time from 6 a.m. to 10 p.m. was considered daily activity period (daytime) with automatic BP measurements in 10-min intervals. During night rest (10 p.m.-6 a.m.) the measurements were performed every 30 min. Patients were recommended to adjust their circadian activity to those periods of time. BP thresholds used to define AH were set according to the ESC guidelines [2] .
Applanation tonometry
The assessment of central BP and augmentation index (AI) was performed noninvasively using the SphygmoCor ® system (AtCor Medical Inc Pty Ltd, Sydney, Australia). Radial artery pressure waveforms were recorded at left wrist using applanation tonometry with a high-fidelity micromanometer (Millar Instruments, Houston, Texas) and processed by SphygmoCor ® software (version 9.0; AtCor Medical Inc Pty Ltd., Sydney, Australia). Corresponding aortic pressure waveform was generated using a validated transfer function [10] . 
Echocardiography
Two-dimensional echocardiography was performed using standard parasternal, apical, and subcostal views (2.5 MHz transducer; VIVID S6 GE Medical System, Wauwatosa, WI, USA). The dimensions of left atrium (LA), left ventricular end diastolic diameter (LVEDD) and interventricular septum diameter were measured in the parasternal long-axis view in the late diastole of the LA and left ventricle (LV), respectively. Left ventricular ejection fraction was calculated according to the Simpson's formula. The left ventricular hypertrophy (LVH) was diagnosed according to the formula recommended by the American Society of Echocardiography for estimation of the left ventricular The following parameters were measured: mitral inflow early (E) and late (A) phase ratio (E/A) and phase E deceleration time. Tissue Doppler imaging was performed in the apical views to acquire mitral annular velocity, mitral septal annulus early diastolic velocity (e') was measured and based on this the E/e' ratio was calculated. Diagnosis of the LV diastolic dysfunction was based on the current guidelines [11] . The study group comprised only of patients with normal and mildly impaired LV diastolic function (impaired relaxation diastolic filling pattern).
Impedance cardiography
All ICG measurements were performed using the Niccomo™ device (Medis, Ilmenau, Germany) after 10 min of rest in a supine position. Blood pressure measurement was performed automatically every 2 min with an arm cuff. Other hemodynamic parameters were measured with a beat-to-beat method. The TFC, CI, SVRI, heart rate (HR) values measured in the 5 th min of the examination were taken into account in the treatment algorithm. 
Treatment
Non-pharmacological treatment was administered according to the current ESC guidelines [2] . The arbitrarily predetermined treatment algorithm in HD group was based on our own data collected in the cohort of hypertensive patients and the analysis of the previous reports [5, 6, 12--15] . Cutoffs for CI and SVRI were adopted from the previous studies of Taler et al. [5] and Smith et al. [6] . Increased rest HR (> 80/min) was considered an indication for BB use due to the fact that it had been reported to be unfavorable for prognosis [15] . The different cut-off values for TFC for men and women were defined based on sex-dependant computational calculation used in Niccomo device.
The first step of drug choice was based on the hemodynamic profile (hyperdynamic profile -BB, hypervolemic -diuretic, hyperconstrictivevasodilator/s). Combined therapy was applied in cases of complex hemodynamic disturbances and to patients demanding combined polytherapy (BP criteria mentioned above). This algorithm was described in detail in our previous study [7] . Patients in the GE group were treated according to the current ESC guidelines [2] . With most patients the first drug choice was ACEI and CB, the most preferred combinations were: ACEI with diuretic and ACEI with CB.
Statistical analysis
On the basis of the results of the previous studies [5] [6] [7] , the sample size for minimum change in BP reduction of 6 mm Hg after 12 months of follow-up was calculated as 45 patients per treatment group (a-error 5%, statistical power 80%). The statistical analysis was performed using Statistica 7.0 (StatSoft, Inc., Tulsa, USA). The distribution and normality of the data were assessed by visual inspection and the Kolmogorov-Smirnov test. Continuous variables were presented as means ± standard deviation. 
Results
Baseline clinical data
The final analysis involved 121 patients (83 men) of average age 46.4 ± 10.1 years (spread from 20 to 68 years). Most of them (81.0%) were mildly hypertensive (grade 1) and only 19.0% of them presented AH grade 2 or 3. 20.7% of them were previously treated with hypotensive drugs.
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Treatment effects -brachial blood pressure
Reduction of BP absolute values due to treatment was observed in both groups. However, no statistically significant difference between GE and HD was noted ( Table 2 ). The benefit from the hemodynamically-guided therapy revealed to be more evident when comparing delta systolic BP (Fig. 2 ) but the differences still did not reach statistical significance. The only statistically significant differences were obtained for the percentage of patients achieving BP reduction of minimum 20 mm Hg for office diastolic BP and mean 24-h systolic BP (Fig. 3) .
Treatment effects -impedance cardiography, applanation tonometry and echocardiography
The use of ICG did not significantly influence the effects of 12-month therapy on other analyzed hemodynamic and echocardiographic characteristics. There were no significant differences between GE and HD in central BP, basic impedance indices (HR, CI, TFC, SVRI), left chamber dimensions (LVEDD, LA), cardiac muscle mass (LVMI) and echocardiographic indices of LV diastolic function (Table 3) . However, the analysis in a subgroup of patients with LV diastolic dysfunction revealed slightly a better effect of hemodynamically-guided intervention -better improvement (change) in E/A (GE vs. HD: 0.12 vs. 0.34, p = 0.017), e' (2.67 vs. 2.13 cm/s, p = 0.699) and E/e' (-0.77 vs. -0.82, p = 0.839). Such an analysis was not performed in the subgroup of patients with LVH because of low sample size (n = 13).
Pharmacotherapy
The most commonly administered drugs in both groups were renin-angiotensin-aldosterone system's blockers (ACEI/ARB) and diuretics ( Table 4 ). The GE patients were more frequently treated with ACEI and CB, whereas the HD patients with diuretics and BB. However, no statistically significant difference was noted. Likewise, the percentage of patients demanding intensification of pharmacotherapy during second visit was comparable (GE vs. HD: 19.7% vs. 18.2%, p = 0.832).
Discussion
Blood pressure control still remains a challenge in AH. Thus, the search for noninvasive tools useful in individualized hemodynamic assessment of hypertensives seems to be justified. We present the results of FINEPATH study which aimed at evaluating whether the beneficial effect of hemodynamically-guided therapy, previously reported in short-term observations, persisted over 1 year and whether it was visible in other clinically relevant characteristics. Our results encourage the use of ICG while choosing the antihypertensive pharmacotherapy. We observed clinically relevant better BP lowering effect and slightly more pronounced improvement of the LV diastolic function in subjects treated according to ICG-based algorithm. No significant differences were observed in left chambers morphology, LV systolic function and central BP.
www.cardiologyjournal.org Table 3 . Treatment effects assessed by impedance cardiography, applanation tonometry and echocardiography; data presented as mean ± standard deviation and numbers (percentages). AI -augmentation index; CI -cardiac index; CDBP -central diastolic blood pressure; CSBP -central systolic blood pressure; CPP -central pulse pressure; e' -mitral septal annulus early diastolic velocity; E/A -mitral flow early (E) and late (A) phase ratio; E/e' -mitral flow early (E) phase and mitral septal annulus early diastolic velocity (e') ratio; HR -heart rate; LA -left atrium diameter; LVEDD -left ventricular end diastolic diameter; LVEF -left ventricular ejection fraction; SVRI -systemic vascular resistance index; TFC -thoracic fluid content 
Blood pressure (brachial) lowering effects
Our results suggest persistent benefit from the hemodynamically-guided antihypertensive therapy. Patients treated according to ICG achieved slightly greater BP reduction in both OBPM and ABPM. That effect was more pronounced among those with higher BP reduction (Fig. 3B) . However, the statistical significance was achieved only for percentage of patients achieving BP reduction of minimum 20 mm Hg for office diastolic BP and mean 24-h systolic BP. The uncertainty of other results seems unlikely because better BP reduction was observed independently in OBPM and ABPM. Even those statistically non-significant differences we interpret as clinically important because a slight decrease in BP revealed to be related to lower risk of overall mortality, coronary disease and stroke [16] . We suppose that the expected benefit from the ICG-guided therapy was limited by sample size and the early stage of AH (see more in 'Limitations of the study' section). We would also like to emphasize that subjects in GE were treated by experienced cardiologists, of higher expertise than general practitioners, which carry the main weight of medical care over young hypertensives. It could cause underestimation of the expected advantage of ICG in the real world of ambulatory care.
Our results are in line with previous studies in this area evaluating the effect of ICG-guided therapy in short-term observation [5] [6] [7] 17] . Smith et al. [6] evaluated 164 patients with essential AH and obtained better office BP control in HD group (77% vs. 57%, p < 0.001). In another prospective, randomized and controlled trial Taler et al. [5] used ICG-based therapy in 104 resistant hypertensives (average BP 171/89 mm Hg) and also achieved higher frequency of goal office BP in HD group (56% vs. 33% in GE group, p < 0.05). Likewise, Fadl Elmula et al. [17] , in a small sample of patients with resistant AH (n = 19), reported better BP lowering effect of pharmacotherapy adjusted to the individual hemodynamic profile than renal denervation. The effect of ICG-guided therapy in aforementioned study was less impressive than ours but the characteristics of our population were also different. Lower baseline BP could significantly limit the disclosure of advantage from individualized treatment. As revealed in our previous analysis the benefit from ICG-guided therapy rose with the complexity of AH and was observed only in subjects with higher baseline BP [18] .
Out-of-brachial BP lowering effects
We did not observe any benefit of the intervention in the analysis of change in the left chamber dimensions and LV muscle mass, as it was reported by Fagard et al. [19] . In that metaanalysis, the reduction of LVMI was clinically relevant (11.0% ± ± 0.60%, p < 0.001) but almost half of the patients (43.6%) presented with baseline LVH. Moreover, the authors proved that regression of LVH was related to longer study duration. No influence of antihypertensive treatment on LVMI in our study cohort can be explained by early stage of cardiovascular dysfunction (hypertensives without any other serious diseases), very low prevalence of LVH (10.7%) and 12-month (quite short) period of follow-up.
The comparative analysis did not reveal any intergroup difference in change of impedance parameters characterizing the hemodynamic profile. However, those results could be influenced by different, even opposite, hemodynamic action of drugs. Relatively high standard deviations of those variables suggest that the individual effects were underestimated by the use of averaging in general comparison. True hemodynamic effects could be revealed in separate analysis of subgroups (treated with different classes of drugs) which was not conducted because of small sample size.
The trend to greater HR reduction in HD could partly explain why the higher brachial BP reduction was not reflected in central BP change. It could be a result of more frequent use of BB in HD which was less effective in central BP lowering than vasodilators (preferred in GE) [20] . The mechanism was explained in a simple manner by Nieminen et al. [21] . Beta-blocker slows down the HR, increases the filling time of the LV and stroke volume. As a result, the pulsatile LV outflow and CPP increase.
Pharmacotherapy
Although some trends in the analysis of pharmacotherapy were observed (subjects in GE were more frequently treated with vasodilators and in HD with diuretics and BB), they did not reveal significant differences between GE and HD. It suggests that in comparison to our previous study [7] , empiric treatment was more intensive. It could partly explain slightly lower advantage of hemodynamically-guided intervention.
Limitations of the study
We are aware that the main limitation of the study was the sample size, which influenced the statistical power of the comparison. Basing on the previous studies [5] [6] [7] we calculated the sample size (45 per group) assuming intergroup difference (GE vs. HD) in delta BP as 6 mm Hg. Finally, the highest observed difference in our analysis was 4.6 mm Hg (delta 24-h mean systolic BP). According to the statistical approach (power analysis), the sample size in this case should not be less than 76 per group. The fact of enrollment of relatively healthy patient cohort also mattered. We are aware that our results should be extrapolated on general population with care because we recruited hypertensives without other serious chronic diseases. On the other hand, the time of follow-up (12 months) might be too short to reveal some of the evaluated long-term effects of the intervention (i.e. heart remodeling).
Conclusions
1. Impedance cardiography offers an effective option of individualized drug selection in AH. 2. Some patients can benefit from the hemodynamically-guided pharmacotherapy in significantly greater BP reduction. 3. The effect of hemodynamically-guided pharmacotherapy persists over time.
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